Evidence map›Paper›PMID 42450219›Full record

ArticleInternational journal of molecular sciences2026

The Effect of Radiofrequency Exposure on the Cytotoxic Activity of Sunitinib and a Novel Sunitinib-Class Compound 4, in Colorectal Cancer Cells.

Ayse Erol Bozkurt, Mediha Suleymanoglu, Tugce Cinek, Nilgun Karali, Sedat Ballikaya, Mehmet Salih Iyikesici, Serap Kuruca

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ayse Erol BozkurtDepartment of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Turkey.ORCID 0000-0003-4454-4651
Mediha SuleymanogluDepartment of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Turkey.ORCID 0000-0002-1401-4863
Tugce CinekDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul Health and Technology University, 34275 Istanbul, Turkey.
Nilgun KaraliDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, 34116 Istanbul, Turkey.
Sedat BallikayaDepartment of Engineering Sciences, Faculty of Engineering, Istanbul University-Cerrahpaşa, 34320 Istanbul, Turkey.
Mehmet Salih IyikesiciDepartment of Medical Oncology, School of Medicine, Altinbas University, 34147 Istanbul, Turkey.
Serap KurucaDepartment of Physiology, Faculty of Medicine, Istanbul Atlas University, 34408 Istanbul, Turkey.ORCID 0000-0001-7878-9994

Funding

Istanbul University TDP-2020-36598Istanbul University TSA-2023-39461
6 · The paper itself

Abstract

Achieving optimal therapeutic efficacy in colorectal cancer (CRC) remains challenging, highlighting the need for novel treatment strategies. This study evaluated whether radiofrequency (RF) hyperthermia enhances the anticancer effects of sunitinib malate and a newly synthesized tyrosine kinase (TK) inhibitor (compound

Indexed as

Antineoplastic AgentsColorectal NeoplasmsIndolesProtein Kinase InhibitorsPyrrolesRadio WavesApoptosisCell Line, TumorCell SurvivalHCT116 CellsHumansHyperthermia, InducedSunitinibAntineoplastic AgentsIndolesProtein Kinase InhibitorsPyrrolesSunitinib2-indolinonecell viabilitycolorectal cancerradiofrequency hyperthermiasunitinibtyrosine kinase inhibitor

Identifiers

PMID42450219
PMCPMC13362021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.